Ardelyx (ARDX) Other financing activities (2014 - 2023)
Ardelyx posted quarterly Other financing activities of $5.0 million for Q4 2023, up 250100.0% on a QoQ basis from -$2000.0 in Q4 2014.
Ardelyx (ARDX) has 2 years of Other financing activities data on file, last reported at $5.0 million in Q4 2023.
- For the quarter ending Q4 2023, Other financing activities changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2023 stood at $5.0 million (changed N/A YoY), and the FY2023 full-year result was $5.0 million, down 47.81% from the prior year.
- Other financing activities for Q4 2023 stood at $5.0 million, up from -$2000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $5.0 million in Q4 2023 and bottomed at $5.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5.00 Mn |
| Dec 31, 2023 | 5.00 Mn |
| Dec 31, 2014 | -2,000.00 |
| Dec 31, 2014 | -2,000.00 |